[go: up one dir, main page]

IL160358A0 - Human antibodies specific for interleukin 15 (il-15) - Google Patents

Human antibodies specific for interleukin 15 (il-15)

Info

Publication number
IL160358A0
IL160358A0 IL16035802A IL16035802A IL160358A0 IL 160358 A0 IL160358 A0 IL 160358A0 IL 16035802 A IL16035802 A IL 16035802A IL 16035802 A IL16035802 A IL 16035802A IL 160358 A0 IL160358 A0 IL 160358A0
Authority
IL
Israel
Prior art keywords
human
human antibodies
antibodies
interleukin
antibodies specific
Prior art date
Application number
IL16035802A
Other languages
English (en)
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab As filed Critical Genmab As
Publication of IL160358A0 publication Critical patent/IL160358A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL16035802A 2001-08-23 2002-08-23 Human antibodies specific for interleukin 15 (il-15) IL160358A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31473101P 2001-08-23 2001-08-23
PCT/US2002/026769 WO2003017935A2 (en) 2001-08-23 2002-08-23 Human antibodies specific for interleukin 15 (il-15)

Publications (1)

Publication Number Publication Date
IL160358A0 true IL160358A0 (en) 2004-07-25

Family

ID=23221192

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16035802A IL160358A0 (en) 2001-08-23 2002-08-23 Human antibodies specific for interleukin 15 (il-15)
IL160358A IL160358A (en) 2001-08-23 2004-02-12 Isolated human monoclonal antibodies specific for interleukin 15 (il-15)

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL160358A IL160358A (en) 2001-08-23 2004-02-12 Isolated human monoclonal antibodies specific for interleukin 15 (il-15)

Country Status (25)

Country Link
US (1) US7153507B2 (da)
EP (1) EP1425389B1 (da)
JP (2) JP4359503B2 (da)
KR (1) KR100911951B1 (da)
CN (1) CN100557018C (da)
AT (1) ATE531390T1 (da)
AU (1) AU2002332628B2 (da)
BR (1) BR0212136A (da)
CA (1) CA2456648C (da)
CY (1) CY1112447T1 (da)
DK (1) DK1425389T3 (da)
EA (1) EA014802B1 (da)
ES (1) ES2375271T3 (da)
HK (1) HK1066828A1 (da)
HU (1) HU229776B1 (da)
IL (2) IL160358A0 (da)
MX (1) MXPA04001486A (da)
NO (1) NO333152B1 (da)
NZ (1) NZ531211A (da)
PL (1) PL217752B1 (da)
PT (1) PT1425389E (da)
RS (1) RS51829B (da)
SI (1) SI1425389T1 (da)
WO (1) WO2003017935A2 (da)
ZA (1) ZA200401144B (da)

Families Citing this family (273)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
ES2375271T3 (es) 2001-08-23 2012-02-28 Genmab A/S Anticuerpos humanos espec�?ficos para interleuquina 15 (il-15).
US7329405B2 (en) 2001-08-23 2008-02-12 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
GB0208817D0 (en) * 2002-04-17 2002-05-29 European Molecular Biology Lab Embl Method for producing monoclonal antibodies
RS20050724A (en) * 2003-02-26 2007-11-15 Genmab A/S., Human antibodies specific for interleukin 15(il-15)
NZ570709A (en) 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
US20050123542A1 (en) * 2003-11-06 2005-06-09 Genmab A/S Methods for treating disorders involving monocytes
US7928205B2 (en) * 2004-10-22 2011-04-19 Amgen Inc. Methods for refolding of recombinant antibodies
WO2006063974A2 (en) * 2004-12-13 2006-06-22 Cytos Biotechnology Ag Il-15 antigen arrays and uses thereof
CA2608728A1 (en) * 2005-05-16 2006-11-23 Abbott Biotechnology Ltd. Use of tnfa inhibitor for treatment of erosive polyarthritis
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
US20070190057A1 (en) * 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
WO2007120656A2 (en) * 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
AU2008216495A1 (en) 2007-02-09 2008-08-21 Genentech, Inc. Anti-Robo4 antibodies and uses therefor
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
AU2008293425B2 (en) * 2007-08-31 2014-09-18 Amgen Inc. Solid-state protein formulation
AU2008298904B2 (en) * 2007-09-14 2014-10-16 Amgen Inc. Homogeneous antibody populations
CA2701032C (en) 2007-09-27 2021-01-26 Amgen Inc. Pharmaceutical formulations
ES2962777T3 (es) 2007-11-15 2024-03-21 Amgen Inc Formulación acuosa de anticuerpos estabilizada por antioxidantes para la administración parenteral
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
EP2098536A1 (en) 2008-03-05 2009-09-09 4-Antibody AG Isolation and identification of antigen- or ligand-specific binding proteins
JP2011517672A (ja) * 2008-03-24 2011-06-16 アボツト・バイオテクノロジー・リミテツド 骨損失を治療するための方法及び組成物
CU23716A1 (es) 2008-09-30 2011-10-05 Ct Ingenieria Genetica Biotech Péptido antagonista de la actividad de la interleucina-15
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
WO2011014457A1 (en) 2009-07-27 2011-02-03 Genentech, Inc. Combination treatments
US9321823B2 (en) 2009-09-02 2016-04-26 Genentech, Inc. Mutant smoothened and methods of using the same
AU2010310457B2 (en) 2009-10-23 2015-07-02 Amgen Inc. Vial adapter and system
TWI505836B (zh) 2009-12-11 2015-11-01 Genentech Inc 抗－ｖｅｇｆ－ｃ抗體及其使用方法
AU2010339770B2 (en) 2009-12-21 2015-02-12 Genentech, Inc. Antibody formulation
SG194370A1 (en) 2010-06-07 2013-11-29 Amgen Inc Drug delivery device
DK2580243T3 (da) 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
SMT201700547T1 (it) 2010-06-15 2018-01-11 Genmab As Coniugati di farmaco anticorpo umano contro il fattore tissutale
US8481680B2 (en) 2010-10-05 2013-07-09 Genentech, Inc. Mutant smoothened and methods of using the same
AU2012236573B2 (en) 2011-03-31 2016-06-02 Amgen Inc. Vial adapter and system
HUE042822T2 (hu) 2011-04-20 2019-07-29 Amgen Inc Automata befecskendezõ szerkezet
CN102250243B (zh) * 2011-07-01 2013-08-28 华绍炳 抗白细胞介素-15抗体
CN103797028B (zh) * 2011-07-18 2017-08-25 Iba 股份有限公司 使靶细胞可逆染色的方法
CA2851521C (en) 2011-10-14 2020-09-22 Amgen Inc. Injector and method of assembly
SI3081249T1 (sl) 2012-11-21 2021-03-31 Amgen Inc. Naprava za dajanje zdravila
CA2899241C (en) 2013-02-20 2023-03-28 Innate Pharma A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma
AR095399A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida, método
RS60534B1 (sr) 2013-03-13 2020-08-31 Hoffmann La Roche Formulacije sa smanjenom oksidacijom
US20140314778A1 (en) 2013-03-13 2014-10-23 Genentech, Inc. Formulations with reduced oxidation
SG11201507475UA (en) 2013-03-13 2015-10-29 Genentech Inc Antibody formulations
EP2968466B1 (en) 2013-03-13 2018-07-25 F.Hoffmann-La Roche Ag Formulations with reduced oxidation
TWI639453B (zh) 2013-03-15 2018-11-01 美商安美基公司 用於注射器之匣盒
TWI592183B (zh) 2013-03-15 2017-07-21 安美基公司 本體輪廓可調適之自動注射器裝置
AU2014233393B2 (en) 2013-03-15 2020-05-28 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
ES2973257T3 (es) 2013-03-15 2024-06-19 Amgen Inc Casete de fármaco, autoinyector y sistema de autoinyector
MX2015013533A (es) 2013-03-22 2016-02-05 Amgen Inc Inyector y metodo de montaje.
AR097791A1 (es) 2013-09-27 2016-04-13 Genentech Inc Formulaciones de anticuerpos anti-pdl1
SG11201602876WA (en) 2013-10-24 2016-05-30 Amgen Inc Injector and method of assembly
US10758683B2 (en) 2013-10-24 2020-09-01 Amgen Inc. Drug delivery system with temperature-sensitive control
RS59659B2 (sr) 2013-12-17 2023-08-31 Hoffmann La Roche Postupci lečenjа raka pomoću аntаgonistа koji vežu osovinu pd-1 i pomoću tаksаnа
MX2016007965A (es) 2013-12-17 2016-10-28 Genentech Inc Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1.
CN105899535A (zh) 2013-12-17 2016-08-24 豪夫迈·罗氏有限公司 用pd-1轴结合拮抗剂和抗cd20抗体治疗癌症的方法
WO2015120075A2 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
JP6588461B2 (ja) 2014-03-31 2019-10-09 ジェネンテック， インコーポレイテッド 抗血管新生剤及びｏｘ４０結合アゴニストを含む併用療法
WO2015171777A1 (en) 2014-05-07 2015-11-12 Amgen Inc. Autoinjector with shock reducing elements
CN113990437A (zh) 2014-06-03 2022-01-28 安姆根有限公司 用于远程处理由药物递送装置收集的数据的系统和方法
EP2963057A1 (en) 2014-07-02 2016-01-06 Calypso Biotech SA Antibodies to IL-15
RU2704611C2 (ru) 2014-09-15 2019-10-30 Дженентек, Инк. Составы на основе антител
EP3206739B1 (en) 2014-10-14 2021-12-01 Amgen Inc. Drug injection device with visual and audio indicators
SG11201703152RA (en) 2014-10-23 2017-05-30 Amgen Inc Reducing viscosity of pharmaceutical formulations
BR112017010198A2 (pt) 2014-11-17 2017-12-26 Genentech Inc terapia de combinação compreendendo agonistas de ligação a ox40 e antagonistas de ligação ao eixo de pd-1
ES2785311T3 (es) 2014-12-19 2020-10-06 Amgen Inc Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario
US10799630B2 (en) 2014-12-19 2020-10-13 Amgen Inc. Drug delivery device with proximity sensor
WO2016126972A1 (en) 2015-02-04 2016-08-11 Genentech, Inc. Mutant smoothened and methods of using the same
MX2017010466A (es) 2015-02-17 2018-06-06 Amgen Inc Dispositivo de administracion de farmacos con sujecion asistida de vacio y/o respuestas.
ES2905870T3 (es) 2015-02-27 2022-04-12 Amgen Inc Dispositivo de suministro de fármacos que tiene un mecanismo de protección de aguja con un umbral de resistencia ajustable al movimiento de la protección de aguja
CA2986263A1 (en) 2015-06-17 2016-12-22 Genentech, Inc. Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
ES2964640T3 (es) 2015-08-13 2024-04-08 Amgen Inc Filtración en profundidad cargada de proteínas de unión al antígeno
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
EP3386573B1 (en) 2015-12-09 2019-10-02 Amgen Inc. Auto-injector with signaling cap
CA3007491A1 (en) 2015-12-30 2017-07-06 Genentech, Inc. Use of tryptophan derivatives for protein formulations
CA3007419A1 (en) 2015-12-30 2017-07-06 Genentech, Inc. Formulations with reduced degradation of polysorbate
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
MX2018008347A (es) 2016-01-08 2018-12-06 Hoffmann La Roche Metodos de tratamiento de canceres positivos para ace utilizando antagonistas de union a eje pd-1 y anticuerpos biespecificos anti-ace/anti-cd3.
WO2017136558A1 (en) 2016-02-04 2017-08-10 Curis, Inc. Mutant smoothened and methods of using the same
JP6430025B2 (ja) 2016-03-15 2018-11-28 中外製薬株式会社 Ｐｄ−１系結合アンタゴニストおよび抗ｇｐｃ３抗体を使用して癌を治療する方法
EP4035711A1 (en) 2016-03-15 2022-08-03 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
EP3455142B1 (en) 2016-05-13 2023-08-09 Amgen Inc. Vial sleeve assembly
US11238150B2 (en) 2016-05-16 2022-02-01 Amgen Inc. Data encryption in medical devices with limited computational capability
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
EP3465124A1 (en) 2016-06-03 2019-04-10 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
US20180002417A1 (en) * 2016-06-15 2018-01-04 Celimmune Llc Methods and Compositions for the Treatment of Celiac Disease, Non-Celiac Gluten Sensitivity, and Refractory Celiac Disease
WO2018004842A1 (en) 2016-07-01 2018-01-04 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
CN109476748B (zh) 2016-08-08 2023-05-23 豪夫迈·罗氏有限公司 用于癌症的治疗和诊断方法
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
WO2018067987A1 (en) 2016-10-06 2018-04-12 Amgen Inc. Reduced viscosity protein pharmaceutical formulations
KR102413592B1 (ko) * 2016-10-21 2022-06-27 암젠 인크 약학적 제형 및 그의 제조 방법
US20200261643A1 (en) 2016-10-25 2020-08-20 Amgen Inc. On-body injector
AR110414A1 (es) 2016-12-21 2019-03-27 Cephalon Inc Anticuerpos que se unen específicamente a il-15 humana y usos de estos
JP7139332B2 (ja) 2016-12-23 2022-09-20 ノバルティス アーゲー 第ｘｉ因子抗体および使用方法
MX2019008432A (es) 2017-01-17 2019-11-18 Amgen Inc Dispositivos de inyeccion y metodos relacionados de uso y ensamblaje.
US11369736B2 (en) 2017-02-17 2022-06-28 Amgen Inc. Cannula insertion and retraction mechanisms
CA3048520A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
MX2019010544A (es) 2017-03-06 2019-10-21 Amgen Inc Dispositivo de administracion de farmacos con caracteristica de prevencion de la activacion.
EP3592402A1 (en) 2017-03-07 2020-01-15 Amgen Inc. Needle insertion by overpressure
SG11201908062QA (en) 2017-03-09 2019-09-27 Amgen Inc Insertion mechanism for drug delivery device
MX2019011416A (es) 2017-03-28 2019-11-01 Amgen Inc Sistema y metodo para conjunto de jeringa y vastago de embolo.
EP3615003A4 (en) 2017-04-24 2021-05-26 University Of Massachusetts Lowell DIAGNOSIS AND TREATMENT OF VITILIGO
MA48464A (fr) 2017-04-28 2020-03-04 Amgen Inc Dipeptides n-acétylés et non acétylés contenant de l'arginine destinés à réduire la viscosité de compositions visqueuses de polypeptides thérapeutiques
CA3066399A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Torque driven drug delivery device
WO2018226515A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
MA49447A (fr) 2017-06-22 2020-04-29 Amgen Inc Réduction des impacts/chocs d'activation d'un dispositif
CA3063921A1 (en) 2017-06-23 2018-12-27 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
ES2972207T3 (es) 2017-07-14 2024-06-11 Amgen Inc Sistema de inserción-retracción de agujas con sistema de resorte de torsión doble
IL271173B2 (en) 2017-07-21 2024-04-01 Amgen Inc Gas permeable sealing element for drug container and methods of assembly
JP7242562B2 (ja) 2017-07-25 2023-03-20 アムジエン・インコーポレーテツド 容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法
JP2020528296A (ja) 2017-07-25 2020-09-24 アムジエン・インコーポレーテツド ギヤモジュールを有する薬物送達デバイス及び関連する組立方法
CA3071636A1 (en) 2017-08-01 2019-02-07 Amgen Inc. Systems and methods for performing a real-time glycan assay of a sample
EP3662287B1 (en) 2017-08-01 2024-02-28 Amgen Inc. Systems and methods for real time preparation of a polypeptide sample for anaylsis with mass spectrometry
US20200164155A1 (en) 2017-08-09 2020-05-28 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
US11077246B2 (en) 2017-08-18 2021-08-03 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
US11759565B2 (en) 2017-10-04 2023-09-19 Amgen Inc. Flow adapter for drug delivery device
EP3691716B1 (en) 2017-10-06 2023-11-29 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
MA50348A (fr) 2017-10-09 2020-08-19 Amgen Inc Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
WO2019090086A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Systems and approaches for sterilizing a drug delivery device
MA50553A (fr) 2017-11-06 2020-09-16 Amgen Inc Dispositif d'administration de médicament avec détection de positionnement et de débit
US12053618B2 (en) 2017-11-06 2024-08-06 Amgen Inc. Fill-finish assemblies and related methods
WO2019094138A1 (en) 2017-11-10 2019-05-16 Amgen Inc. Plungers for drug delivery devices
CN111278487B (zh) 2017-11-16 2022-06-24 安进公司 用于药物递送装置的门闩锁机构
JP2021503311A (ja) 2017-11-16 2021-02-12 アムジエン・インコーポレーテツド 失速及び終点検出を有するオートインジェクタ
EP3740264A1 (en) 2018-01-17 2020-11-25 Amgen Inc. Drug delivery mechanism
ES2993017T3 (en) 2018-03-07 2024-12-20 Amgen Inc Controlled dispense syringe
EP3762067A1 (en) 2018-03-09 2021-01-13 Amgen Inc. Backflow prevention mechanism for drug delivery device
IL277106B2 (en) 2018-03-13 2024-03-01 Amgen Inc Sequential digestion of polypeptides for mass spectrometric analysis
JP2021516672A (ja) 2018-03-13 2021-07-08 アムジエン・インコーポレーテツド 質量分光測定分析のためのトリプシン耐性ポリペプチドを調製するための方法
ES2956287T3 (es) 2018-03-30 2023-12-18 Amgen Inc Inspección de contenedores de fármacos mediante cámaras
US11583633B2 (en) 2018-04-03 2023-02-21 Amgen Inc. Systems and methods for delayed drug delivery
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
KR20210024550A (ko) 2018-06-23 2021-03-05 제넨테크, 인크. Pd-1 축 결합 길항제, 백금 제제, 및 토포이소머라제 ii 억제제를 이용한 폐암 치료 방법
EP3823611A1 (en) 2018-07-18 2021-05-26 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
WO2020023444A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
US20210128844A1 (en) 2018-07-24 2021-05-06 Amgen Inc. Delivery devices for administering drugs
US20210260279A1 (en) 2018-07-24 2021-08-26 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
MA53320A (fr) 2018-07-31 2021-11-03 Amgen Inc Ensemble de trajet de fluide pour dispositif d'administration de médicament
SG11202100601TA (en) 2018-08-08 2021-02-25 Genentech Inc Use of tryptophan derivatives and l-methionine for protein formulation
CN112469455B (zh) 2018-08-17 2024-03-22 安进公司 用于药物递送装置的启动机构
EP4249917A3 (en) 2018-09-21 2023-11-08 F. Hoffmann-La Roche AG Diagnostic methods for triple-negative breast cancer
WO2020068623A1 (en) 2018-09-24 2020-04-02 Amgen Inc. Interventional dosing systems and methods
IL281469B2 (en) 2018-09-28 2024-08-01 Amgen Inc Muscle wire escapement activation assembly for a drug delivery device
IL281712B2 (en) 2018-10-02 2025-03-01 Amgen Inc Injection systems for drug delivery with internal power transmission
AU2019355979B2 (en) 2018-10-05 2024-12-05 Amgen Inc. Drug delivery device having dose indicator
IL281894B2 (en) 2018-10-15 2024-12-01 Amgen Inc Drug delivery device having damping mechanism
AR116703A1 (es) 2018-10-15 2021-06-02 Amgen Inc Proceso de ensamblaje de plataforma para un dispositivo de administración de fármacos
EP3873566B1 (en) 2018-11-01 2024-11-27 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
WO2020091981A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
WO2020124008A1 (en) 2018-12-14 2020-06-18 Amgen Inc. System suitability method for use with protein concentration determination by slope
US11534547B2 (en) 2019-01-24 2022-12-27 Amgen Inc. Drug delivery systems and methods with pressure sensitive control
JP7483723B2 (ja) 2019-01-24 2024-05-15 アムジエン・インコーポレーテツド 背圧検知による薬剤送達のシステム及び方法
WO2020167910A1 (en) 2019-02-12 2020-08-20 Amgen Inc. Systems and approaches for drug delivery device reconstitution
MX2021007723A (es) 2019-02-12 2021-08-05 Amgen Inc Sistemas y enfoques de dosificacion continua.
WO2020167541A1 (en) 2019-02-12 2020-08-20 Amgen Inc. Dosing systems and approaches
EP3924016A1 (en) 2019-02-12 2021-12-22 Amgen Inc. Continuous dosing systems and approaches
WO2020167703A1 (en) 2019-02-12 2020-08-20 Amgen Inc. Continuous dosing systems and approaches
US20200254173A1 (en) 2019-02-12 2020-08-13 Amgen Inc. Take-home drug delivery system
JP7483731B2 (ja) 2019-02-14 2024-05-15 アムジエン・インコーポレーテツド 試料の調製及びその試料のリアルタイムアッセイの実施のためのシステム及び方法
WO2020172293A1 (en) 2019-02-20 2020-08-27 Amgen Inc. Methods of determining protein stability
EP3935396A1 (en) 2019-03-04 2022-01-12 Amgen Inc. In vivo reversibility of high molecular weight species
US12078701B2 (en) 2019-03-27 2024-09-03 Amgen Inc. Methods of fingerprinting therapeutic proteins via a two-dimensional (2D) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products
WO2020210094A1 (en) 2019-04-08 2020-10-15 Amgen Inc. Automated drug delivery device and container
CA3130603A1 (en) 2019-04-09 2020-10-15 Amgen Inc. Drug delivery device with smart grip
MX2021012476A (es) 2019-04-17 2021-11-12 Amgen Inc Cartucho para un autoinyector y metodos relacionados.
JP7510952B2 (ja) 2019-04-24 2024-07-04 アムジエン・インコーポレーテツド シリンジ滅菌確認アセンブリ及び方法
EP3958925A1 (en) 2019-04-24 2022-03-02 Amgen Inc. Injector accessories
AU2020288652A1 (en) 2019-06-05 2021-11-18 Amgen Inc. Methods of identifying attributes of therapeutic proteins
JP2022536898A (ja) 2019-06-12 2022-08-22 アスクジーン・ファーマ・インコーポレイテッド 新規ｉｌ－１５プロドラッグおよびその使用方法
MX2021015571A (es) 2019-06-20 2022-01-24 Amgen Inc Dispositivo y metodo de administracion de farmacos habilitados para comunicacion inalambrica.
WO2021011717A1 (en) 2019-07-18 2021-01-21 Amgen Inc. Sealing arrangement for drug delivery device
US20220362474A1 (en) 2019-07-18 2022-11-17 Amgen Inc. Drug delivery device having pressurized vessel
AU2020321951A1 (en) 2019-08-01 2022-02-17 Amgen Inc. Drug delivery device with temperature measurement and related method
AU2020337250A1 (en) 2019-08-23 2022-03-03 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
US12059555B2 (en) 2019-09-03 2024-08-13 Amgen Inc. Injection device for drug delivery and packaging for the injection device
US20220288318A1 (en) 2019-09-03 2022-09-15 Amgen Inc. Activatable injection device for drug delivery
US20220362462A1 (en) 2019-09-12 2022-11-17 Amgen Inc. Backflow Prevention Mechanism for Drug Delivery Device
US12233177B2 (en) 2019-09-16 2025-02-25 Amgen Inc. Method for external sterilization of drug delivery device
MX2022003802A (es) 2019-09-30 2022-04-29 Amgen Inc Dispositivo de administracion de farmacos.
WO2021067209A1 (en) 2019-09-30 2021-04-08 Amgen Inc. Drug delivery device
AU2020359434A1 (en) 2019-09-30 2022-03-17 Amgen Inc. Drug delivery device
AU2020360255A1 (en) 2019-09-30 2022-03-17 Amgen Inc. Drug delivery device
MX2022003743A (es) 2019-09-30 2022-05-02 Amgen Inc Dispositivo de administracion de farmacos.
US20210093792A1 (en) 2019-09-30 2021-04-01 Amgen Inc. Drug delivery device and methods of delivering a drug
US12208943B2 (en) * 2019-10-07 2025-01-28 Amgen Inc. Packages for pharmaceutical products and methods of assembly
EP4041347A1 (en) 2019-10-07 2022-08-17 Amgen Inc. Drug delivery device with fingerprint sensor
WO2021071780A1 (en) 2019-10-07 2021-04-15 Amgen Inc. Drug delivery devices having light-activated ultrasonic fluid delivery
EP4041342A1 (en) 2019-10-07 2022-08-17 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2021071694A1 (en) 2019-10-08 2021-04-15 Amgen Inc. Temperature indicator for drug delivery device
EP4041352A1 (en) 2019-10-08 2022-08-17 Amgen Inc. Cassette for an autoinjector and related methods
US20240082502A1 (en) 2019-10-08 2024-03-14 Amgen Inc. Drug delivery device
EP4041341A1 (en) 2019-10-08 2022-08-17 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2021076540A1 (en) 2019-10-18 2021-04-22 Amgen Inc. Drug delivery device and system
US20240091440A1 (en) 2019-10-18 2024-03-21 Amgen Inc. Drug delivery device and system
MX2022004483A (es) 2019-10-18 2022-05-06 Amgen Inc Sistemas y enfoques para reconstitucion en dispositivo de administracion de farmacos.
CA3153762A1 (en) 2019-10-18 2021-04-22 Amgen Inc. Systems and approaches for drug delivery device reconstitution
US20220401643A1 (en) 2019-10-21 2022-12-22 Amgen Inc. Drug product container and drug delivery system
EP4049012A1 (en) 2019-10-24 2022-08-31 Amgen Inc. Systems and approaches for drug delivery
WO2021081186A1 (en) 2019-10-24 2021-04-29 Amgen Inc. Drug delivery device and system
US20220387700A1 (en) 2019-10-24 2022-12-08 Amgen Inc. Systems and methods for drug delivery
WO2021081283A1 (en) 2019-10-24 2021-04-29 Amgen Inc. Drug delivery device
WO2021081161A1 (en) 2019-10-24 2021-04-29 Amgen Inc. Systems and components for drug delivery and components for preparation of the same
WO2021091749A1 (en) 2019-11-07 2021-05-14 Amgen Inc. Drug delivery system and method of use
WO2021113101A1 (en) 2019-12-02 2021-06-10 Amgen Inc. Lockout mechanism for drug delivery device
WO2021113070A1 (en) 2019-12-05 2021-06-10 Amgen Inc, Flow restrictor for drug delivery device
CA3165927A1 (en) 2020-01-11 2021-07-15 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
CN114901330A (zh) 2020-01-13 2022-08-12 美国安进公司 针头护罩移除器、药物递送装置、以及相关方法
CA3167020A1 (en) 2020-02-24 2021-09-02 Amgen Inc. Containers and systems for use during external sterilization of drug delivery devices
JP2023523133A (ja) 2020-03-16 2023-06-02 アムジエン・インコーポレーテツド 薬物送達部材挿入検知アセンブリ、薬物送達デバイス、及び関連方法
JP2023518226A (ja) 2020-03-17 2023-04-28 アムジエン・インコーポレーテツド 制御型吐出シリンジ
EP4143811A1 (en) 2020-04-28 2023-03-08 Amgen Inc. Packaging label
EP4153922A1 (en) 2020-05-22 2023-03-29 Amgen Inc. Storage system and method for storing and transporting medicament
IL299039A (en) 2020-06-16 2023-02-01 Genentech Inc Methods and preparations for the treatment of triple-negative breast cancer
BR112023003947A2 (pt) 2020-09-02 2023-04-11 Amgen Inc Mecanismo de abertura fácil para embalagem cartonada de armazenamento de medicamentos
WO2022055779A1 (en) 2020-09-09 2022-03-17 Amgen Inc. Swallowable drug delivery devices
WO2022055761A1 (en) 2020-09-11 2022-03-17 Amgen Inc. Inline uv flow device for sterilizing flow cytometry sheath fluid
CA3195365A1 (en) 2020-09-18 2022-03-24 Amgen Inc. Methods of processing a sample for peptide mapping analysis
CA3192737A1 (en) 2020-10-12 2022-04-21 Amgen Inc. Long-term medicament storage apparatus and methods
MX2023005061A (es) 2020-11-04 2023-05-12 Amgen Inc Ensamblaje de dispositivo de administracion de farmacos y accesorio para dispositivo de administracion de farmacos.
US20230381424A1 (en) 2020-11-04 2023-11-30 Amgen Inc. Drug delivery device assembly and accessory for drug delivery device
AU2021374583A1 (en) 2020-11-04 2023-04-20 Amgen Inc. Drug delivery device assembly and accessory for drug delivery device
MX2023005067A (es) 2020-11-04 2023-05-16 Amgen Inc Ensamblaje de dispositivo de administracion de farmacos y accesorio para dispositivo de administracion de farmacos.
JP2023549113A (ja) 2020-11-05 2023-11-22 アムジエン・インコーポレーテツド タンパク質を処理するための材料及び方法
EP4288197A1 (en) 2021-02-03 2023-12-13 Amgen Inc. Systems and approaches for drug processing
WO2022169725A1 (en) 2021-02-03 2022-08-11 Amgen Inc. High-throughput automated reconstitution of lyophilized drug product
EP4288017A1 (en) 2021-02-03 2023-12-13 Amgen Inc. Coaxial needle adapter and guide bracket for robotic liquid handling platform
EP4467314A3 (en) 2021-03-08 2025-02-19 Amgen Inc. Manufacturing process for hollow plunger rod
BR112023018234A2 (pt) 2021-03-10 2023-10-24 Amgen Inc Dispositivo de administração de fármaco tendo uma tampa removível
EP4304684A1 (en) 2021-03-10 2024-01-17 Amgen Inc. Drug delivery device
US20220288326A1 (en) 2021-03-10 2022-09-15 Amgen Inc. Drug delivery device, subassembly for drug delivery device, syringe holder, and method of assembly
BR112023019565A2 (pt) 2021-03-25 2023-11-14 Amgen Inc Dispositivo de administração de fármacos
CN117062640A (zh) 2021-03-31 2023-11-14 美国安进公司 用于药物递送装置的基于声音检测的注射时间测量系统
IL305562A (en) 2021-04-22 2023-10-01 Amgen Inc Methods and systems for automated syringe quality evaluation
CA3213303A1 (en) 2021-04-28 2022-11-03 Amgen Inc. Systems for out-patient treatment of a patient, and related methods
WO2022245574A1 (en) 2021-05-17 2022-11-24 Amgen Inc. Feedback system and method for a drug product
EP4341161A1 (en) 2021-05-21 2024-03-27 Amgen Inc. Method of optimizing a filling recipe for a drug container
EP4348141A1 (en) 2021-06-01 2024-04-10 Amgen Inc. Lyophilization system
AU2022288864A1 (en) 2021-06-08 2023-10-19 Amgen Inc. Drug delivery devices, finger-grip elements, and related methods
EP4355395A1 (en) 2021-06-17 2024-04-24 Amgen Inc. Drug delivery device having shock absorber
AR126197A1 (es) 2021-06-23 2023-09-27 Amgen Inc Jeringuillas, conjuntos y métodos de fabricación referencias a la solicitud relacionada
US20240269380A1 (en) 2021-06-28 2024-08-15 Amgen Inc. Safety device for drug delivery system
EP4370087A1 (en) 2021-07-16 2024-05-22 Amgen Inc. Systems and approaches for drug processing single-use hardware
MX2024003851A (es) 2021-09-29 2024-04-18 Amgen Inc Aparatos, sistemas y metodos para medicion de profundidad de embolo-tapon en jeringas precargadas.
JP2024537115A (ja) 2021-10-06 2024-10-10 アムジエン・インコーポレーテツド 薬物送達デバイスのための衝撃作動保持機能
US20240424223A1 (en) 2021-10-06 2024-12-26 Amgen Inc. Impact Activated Brake Feature for Drug Delivery Device
WO2023064119A1 (en) 2021-10-11 2023-04-20 Amgen Inc. Characterization apparatus for drug delivery devices or subcomponents thereof
TW202327677A (zh) 2021-11-05 2023-07-16 美商安進公司 藥物遞送裝置、供藥物遞送裝置內使用的部件以及操作藥物遞送裝置之方法
WO2023086793A1 (en) 2021-11-09 2023-05-19 Amgen Inc. Production of therapeutic proteins
MX2024006469A (es) 2021-11-29 2024-06-11 Amgen Inc Metodo y aditamento de fuerza de extraccion del vastago del embolo.
JP2024544061A (ja) 2021-12-03 2024-11-27 アムジエン・インコーポレーテツド シリンジ内のストッパ配置
MX2024011034A (es) 2022-03-11 2024-09-18 Amgen Inc Autoinyector de profundidad regulable.
WO2023196111A1 (en) 2022-04-06 2023-10-12 Amgen Inc. Packaging for drug delivery device
IL318532A (en) 2022-08-04 2025-03-01 Novartis Pharma Ag IL-15 inhibitors are useful for treating atopic dermatitis
WO2024040020A1 (en) 2022-08-15 2024-02-22 Absci Corporation Quantitative affinity activity specific cell enrichment
WO2024039575A1 (en) 2022-08-18 2024-02-22 Amgen Inc. Needle shield for syringe
AU2023324704A1 (en) 2022-08-18 2025-01-16 Amgen Inc. Needle shield assembly for a syringe
AU2023333370A1 (en) 2022-08-30 2025-01-16 Amgen Inc. System and method of limiting subvisible particles in a syringe
WO2024228970A1 (en) 2023-05-01 2024-11-07 Amgen Inc. Configurable handheld biological analyzers for identification of biological products based on raman spectroscopy using artificial intelligence
WO2024259275A1 (en) 2023-06-14 2024-12-19 Bristol-Myers Squibb Company Near real time sialic acid quantitation of glycoproteins
WO2025019224A1 (en) 2023-07-14 2025-01-23 Amgen Inc. Monitoring systems and methods for injection devices
CN117209605B (zh) * 2023-11-09 2024-01-30 北京百普赛斯生物科技股份有限公司 特异性结合il-15的抗体及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991010741A1 (en) * 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US6255458B1 (en) * 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5574138A (en) 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US5591630A (en) * 1994-05-06 1997-01-07 Immunex Corporation Monoclonal antibodies that bind interleukin-15 receptors
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US6258352B1 (en) 1995-04-02 2001-07-10 Chugai Seiyaku Kabushiki Kaisha Compositions and methods of treating thrombocytopenia with IL-15
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5660824A (en) 1995-05-24 1997-08-26 Grabstein; Kenneth H. Muscle trophic factor
US6001973A (en) 1996-04-26 1999-12-14 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
JP2001503253A (ja) 1996-10-17 2001-03-13 イムノメディクス，インコーポレイテッド 非抗原性即素複合体およびインターナライジング受容体システムの融合タンパク
DE69830257T3 (de) 1997-02-21 2009-10-15 Amgen Inc., Thousand Oaks Verwendung von Interleukin-15
EP1707051B1 (en) * 1997-02-28 2010-01-13 Kyowa Hakko Kirin Co., Ltd. Human chromosome fragment, and vector containing it
GB9814892D0 (en) 1998-07-10 1998-09-09 Kennedy Rheumatology Inst Treatment of celiac disease
WO2001002003A1 (en) * 1999-07-06 2001-01-11 Bulfone Paus Silvia Method of treating psoriasis with il-15 antagonist
ES2375271T3 (es) 2001-08-23 2012-02-28 Genmab A/S Anticuerpos humanos espec�?ficos para interleuquina 15 (il-15).

Also Published As

Publication number Publication date
JP2009256354A (ja) 2009-11-05
IL160358A (en) 2010-12-30
ATE531390T1 (de) 2011-11-15
SI1425389T1 (sl) 2012-02-29
DK1425389T3 (da) 2012-01-30
EP1425389A4 (en) 2007-08-01
YU15104A (sh) 2006-08-17
KR20040047796A (ko) 2004-06-05
CN1571836A (zh) 2005-01-26
EA200400345A1 (ru) 2004-12-30
CA2456648C (en) 2011-08-16
EP1425389A2 (en) 2004-06-09
EP1425389B1 (en) 2011-11-02
CA2456648A1 (en) 2003-03-06
WO2003017935A2 (en) 2003-03-06
CN100557018C (zh) 2009-11-04
BR0212136A (pt) 2004-12-07
PL217752B1 (pl) 2014-08-29
HU229776B1 (hu) 2014-07-28
PT1425389E (pt) 2012-02-07
HUP0402653A2 (hu) 2005-03-29
WO2003017935A3 (en) 2003-08-14
RS51829B (sr) 2012-02-29
NO20040752L (no) 2004-04-24
KR100911951B1 (ko) 2009-08-13
WO2003017935A9 (en) 2003-04-10
CY1112447T1 (el) 2015-12-09
US7153507B2 (en) 2006-12-26
JP2005503151A (ja) 2005-02-03
HK1066828A1 (en) 2005-04-01
NZ531211A (en) 2007-04-27
PL371946A1 (en) 2005-07-11
EA014802B1 (ru) 2011-02-28
NO333152B1 (no) 2013-03-18
ES2375271T3 (es) 2012-02-28
ZA200401144B (en) 2005-05-12
HUP0402653A3 (en) 2010-01-28
AU2002332628B2 (en) 2007-07-26
MXPA04001486A (es) 2004-10-27
US20030138421A1 (en) 2003-07-24
JP4359503B2 (ja) 2009-11-04

Similar Documents

Publication Publication Date Title
HK1066828A1 (en) Human antibodies specific for interleukin 15 (il-15)
LTPA2021514I1 (da)
TW200500378A (en) Human antibodies specific for interleukin 15 (IL-15)
HK1082749A1 (en) Human monoclonal antibodies against interleukin 8 (il-8)
AU2003303237A8 (en) Human monoclonal antibodies to epidermal growth factor receptor (egfr)
HK1049015A1 (en) Human monoclonal antibodies to prostate specific membrane antigen
WO2003064606A3 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
MXPA05012571A (es) Anticuerpos monoclonales humanos contra el antigeno protector de bacillus anthracis.
WO2004043989A3 (en) Human monoclonal antibodies to heparanase
RS20050724A (en) Human antibodies specific for interleukin 15(il-15)